Enhanced histamine H2 excitation of striatal cholinergic interneurons in l-DOPA-induced dyskinesia

Neurobiology of Disease

Volumn 76, Issue , 2015, Pages 67-76

  Lim, Sean Austin O ^a   Xia, Rong ^a   Ding, Yunmin ^a,b   Won, Lisa ^a   Ray, William J ^c   Hitchcock, Stephen A ^c   McGehee, Daniel S ^a   Kang, Un Jung ^a,b  

^a UNIVERSITY OF CHICAGO   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c Envoy Therapeutics   (United States)

Author keywords

6 OHDA lesion; Aphakia; Cholinergic interneuron; Famotidine; Histamine; L DOPA induced dyskinesia; Parkinson's disease; Striatum

Indexed keywords

DICYCLOVERINE; FAMOTIDINE; HISTAMINE H2 RECEPTOR; LEVODOPA; HISTAMINE H2 RECEPTOR ANTAGONIST;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLINERGIC NERVE CELL; CHOLINERGIC RECEPTOR BLOCKING; CHOLINERGIC TRANSMISSION; CONTROLLED STUDY; CORPUS STRIATUM; DYSKINESIA; INTERNEURON; MALE; MOUSE; NERVE CELL EXCITABILITY; NERVE CELL STIMULATION; NONHUMAN; PARKINSON DISEASE; PROTEIN EXPRESSION; ACTION POTENTIAL; ANIMAL; C57BL MOUSE; COMPLICATION; DISEASE MODEL; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ACTION POTENTIALS; ANIMALS; CHOLINERGIC NEURONS; CORPUS STRIATUM; DICYCLOMINE; DISEASE MODELS, ANIMAL; DYSKINESIA, DRUG-INDUCED; FAMOTIDINE; HISTAMINE H2 ANTAGONISTS; INTERNEURONS; LEVODOPA; MICE; MICE, INBRED C57BL; PARKINSON DISEASE; RECEPTORS, HISTAMINE H2;

EID: 84923092065     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2015.01.003     Document Type: Article

References (60)

1. Anichtchik O.V., Rinne J.O., Kalimo H., Panula P. An altered histaminergic innervation of the substantia nigra in Parkinson's disease. Exp. Neurol. 2000, 163:20-30. 10.1006/exnr.2000.7362.
2. Aosaki T., Tsubokawa H., Ishida A., Watanabe K., Graybiel A.M., Kimura M. Responses of tonically active neurons in the primate's striatum undergo systematic changes during behavioral sensorimotor conditioning. J. Neurosci. Off. J. Soc. Neurosci. 1994, 14:3969-3984.
3. Aosaki T., Kimura M., Graybiel A.M. Temporal and spatial characteristics of tonically active neurons of the primate's striatum. J. Neurophysiol. 1995, 73:1234-1252.
4. Bell M.I., Richardson P.J., Lee K. Histamine depolarizes cholinergic interneurones in the rat striatum via a H(1)-receptor mediated action. Br. J. Pharmacol. 2000, 131:1135-1142. 10.1038/sj.bjp.0703692.
5. Bennett B.D., Wilson C.J. Spontaneous activity of neostriatal cholinergic interneurons in vitro. J. Neurosci. Off. J. Soc. Neurosci. 1999, 19:5586-5596.
6. Birket-Smith E. Abnormal involuntary movements induced by anticholinergic therapy. Acta Neurol. Scand. 1974, 50:801-811.
7. Bolam J.P., Wainer B.H., Smith A.D. Characterization of cholinergic neurons in the rat neostriatum. A combination of choline acetyltransferase immunocytochemistry, Golgi-impregnation and electron microscopy. Neuroscience 1984, 12:711-718.
8. Bordia T., Campos C., Huang L., Quik M. Continuous and intermittent nicotine treatment reduces l-3,4-dihydroxyphenylalanine (l-DOPA)-induced dyskinesias in a rat model of Parkinson's disease. J. Pharmacol. Exp. Ther. 2008, 327:239-247. 10.1124/jpet.108.140897.
9. Bordia T., Campos C., McIntosh J.M., Quik M. Nicotinic receptor-mediated reduction in l-DOPA-induced dyskinesias may occur via desensitization. J. Pharmacol. Exp. Ther. 2010, 333:929-938. 10.1124/jpet.109.162396.
10. Calabresi P., Centonze D., Gubellini P., Pisani A., Bernardi G. Acetylcholine-mediated modulation of striatal function. Trends Neurosci. 2000, 23:120-126.
11. Chang J.W., Wachtel S.R., Young D., Kang U.J. Biochemical and anatomical characterization of forepaw adjusting steps in rat models of Parkinson's disease: studies on medial forebrain bundle and striatal lesions. Neuroscience 1999, 88:617-628.
12. Chartoff E.H., et al. Induction of stereotypy in dopamine-deficient mice requires striatal D1 receptor activation. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:10451-10456.
13. Conti M.M., Ostock C.Y., Lindenbach D., Goldenberg A.A., Kampton E., Dell'isola R., Katzman A.C., Bishop C. Effects of prolonged selective serotonin reuptake inhibition on the development and expression of l-DOPA-induced dyskinesia in hemi-parkinsonian rats. Neuropharmacology 2014, 77:1-8. 10.1016/j.neuropharm.2013.09.017.
14. Ding Y., Restrepo J., Won L., Hwang D.-Y., Kim K.-S., Kang U.J. Chronic 3,4-dihydroxyphenylalanine treatment induces dyskinesia in aphakia mice, a novel genetic model of Parkinson's disease. Neurobiol. Dis. 2007, 27:11-23. 10.1016/j.nbd.2007.03.013.
15. Ding Y., Won L., Britt J.P., Lim S.A.O., McGehee D.S., Kang U.J. Enhanced striatal cholinergic neuronal activity mediates l-DOPA-induced dyskinesia in parkinsonian mice. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:840-845. 10.1073/pnas.1006511108.
16. Doyle J.P., Dougherty J.D., Heiman M., Schmidt E.F., Stevens T.R., Ma G., Bupp S., Shrestha P., Shah R.D., Doughty M.L., Gong S., Greengard P., Heintz N. Application of a translational profiling approach for the comparative analysis of CNS cell types. Cell 2008, 135:749-762. 10.1016/j.cell.2008.10.029.
17. Ellender T.J., Huerta-Ocampo I., Deisseroth K., Capogna M., Bolam J.P. Differential modulation of excitatory and inhibitory striatal synaptic transmission by histamine. J. Neurosci. Off. J. Soc. Neurosci. 2011, 31:15340-15351. 10.1523/JNEUROSCI. 3144-11.2011.
18. Espadas I., Darmopil S., Vergaño-Vera E., Ortiz O., Oliva I., Vicario-Abejón C., Martín E.D., Moratalla R. l-DOPA-induced increase in TH-immunoreactive striatal neurons in parkinsonian mice: insights into regulation and function. Neurobiol. Dis. 2012, 48:271-281. 10.1016/j.nbd.2012.07.012.
19. Farrar A.M., Callahan J.W., Abercrombie E.D. Reduced striatal acetylcholine efflux in the R6/2 mouse model of Huntington's disease: an examination of the role of altered inhibitory and excitatory mechanisms. Exp. Neurol. 2011, 232:119-125. 10.1016/j.expneurol.2011.08.010.
20. Feng Z.-J., Zhang X., Chergui K. Allosteric modulation of NMDA receptors alters neurotransmission in the striatum of a mouse model of Parkinson's disease. Exp. Neurol. 2014, 255:154-160. 10.1016/j.expneurol.2014.03.001.
21. Fernandez H.H. Updates in the medical management of Parkinson disease. Cleve. Clin. J. Med. 2012, 79:28-35. 10.3949/ccjm.78gr.11005.
22. Giachetti A., Giraldo E., Ladinsky H., Montagna E. Binding and functional profiles of the selective M1 muscarinic receptor antagonists trihexyphenidyl and dicyclomine. Br. J. Pharmacol. 1986, 89:83-90.
23. Gomez-Ramirez J., Johnston T.H., Visanji N.P., Fox S.H., Brotchie J.M. Histamine H3 receptor agonists reduce l-dopa-induced chorea, but not dystonia, in the MPTP-lesioned nonhuman primate model of Parkinson's disease. Mov. Disord. Off. J. Mov. Disord. Soc. 2006, 21:839-846. 10.1002/mds.20828.
24. Gras C., Amilhon B., Lepicard E.M., Poirel O., Vinatier J., Herbin M., Dumas S., Tzavara E.T., Wade M.R., Nomikos G.G., Hanoun N., Saurini F., Kemel M.-L., Gasnier B., Giros B., El Mestikawy S. The vesicular glutamate transporter VGLUT3 synergizes striatal acetylcholine tone. Nat. Neurosci. 2008, 11:292-300. 10.1038/nn2052.
25. Haas H.L., Sergeeva O.A., Selbach O. Histamine in the nervous system. Physiol. Rev. 2008, 88:1183-1241. 10.1152/physrev.00043.2007.
26. Hauser R.A., Rascol O., Korczyn A.D., Jon Stoessl A., Watts R.L., Poewe W., De Deyn P.P., Lang A.E. Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. Mov. Disord. Off. J. Mov. Disord. Soc. 2007, 22:2409-2417. 10.1002/mds.21743.
27. Hill S.J. Distribution, properties, and functional characteristics of three classes of histamine receptor. Pharmacol. Rev. 1990, 42:45-83.
28. Hwang D.-Y., Ardayfio P., Kang U.J., Semina E.V., Kim K.-S. Selective loss of dopaminergic neurons in the substantia nigra of Pitx3-deficient aphakia mice. Brain Res. Mol. Brain Res. 2003, 114:123-131.
29. Hwang D.-Y., Fleming S.M., Ardayfio P., Moran-Gates T., Kim H., Tarazi F.I., Chesselet M.-F., Kim K.-S. 3,4-dihydroxyphenylalanine reverses the motor deficits in Pitx3-deficient aphakia mice: behavioral characterization of a novel genetic model of Parkinson's disease. J. Neurosci. Off. J. Soc. Neurosci. 2005, 25:2132-2137. 10.1523/JNEUROSCI. 3718-04.2005.
30. Jenner P. Molecular mechanisms of l-DOPA-induced dyskinesia. Nat. Rev. Neurosci. 2008, 9:665-677. 10.1038/nrn2471.
31. Johnston T.H., van der Meij A., Brotchie J.M., Fox S.H. Effect of histamine H2 receptor antagonism on levodopa-induced dyskinesia in the MPTP-macaque model of Parkinson's disease. Mov. Disord. Off. J. Mov. Disord. Soc. 2010, 25:1379-1390. 10.1002/mds.23069.
32. Kawaguchi Y. Physiological, morphological, and histochemical characterization of three classes of interneurons in rat neostriatum. J. Neurosci. 1993, 13:4908-4923.
33. Kim D.S., et al. Dopamine-deficient mice are hypersensitive to dopamine receptor agonists. J. Neurosci. 2000, 20:4405-4413.
34. Kimura M., Rajkowski J., Evarts E. Tonically discharging putamen neurons exhibit set-dependent responses. Proc. Natl. Acad. Sci. U. S. A. 1984, 81:4998-5001.
35. Köhler C., Swanson L.W., Haglund L., Wu J.Y. The cytoarchitecture, histochemistry and projections of the tuberomammillary nucleus in the rat. Neuroscience 1985, 16:85-110.
36. Lundblad M., et al. A model of l-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function. Neurobiol. Dis. 2004, 16:110-123.
37. Lundblad M., et al. Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia. Exp. Neurol. 2005, 194:66-75.
38. Martinez-Mir M.I., et al. Loss of striatal histamine H2 receptors in Huntington's chorea but not in Parkinson's disease: comparison with animal models. Synapse 1993, 15:209-220.
39. Munakata M., Akaike N. Regulation of K+ conductance by histamine H1 and H2 receptors in neurones dissociated from rat neostriatum. J. Physiol. 1994, 480(Pt 2):233-245.
40. Nelson A.B., Bussert T.G., Kreitzer A.C., Seal R.P. Striatal cholinergic neurotransmission requires VGLUT3. J. Neurosci. Off. J. Soc. Neurosci. 2014, 34:8772-8777. 10.1523/JNEUROSCI. 0901-14.2014.
41. Nicholas A.P. Levodopa-induced hyperactivity in mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Mov. Disord. 2007, 22:99-104.
42. Nowak P., Noras L., Jochem J., Szkilnik R., Brus H., Körossy E., Drab J., Kostrzewa R.M., Brus R. Histaminergic activity in a rodent model of Parkinson's disease. Neurotox. Res. 2009, 15:246-251. 10.1007/s12640-009-9025-1.
43. Nunes I., Tovmasian L.T., Silva R.M., Burke R.E., Goff S.P. Pitx3 is required for development of substantia nigra dopaminergic neurons. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:4245-4250. 10.1073/pnas.0230529100.
44. Nuutinen S., Panula P. Histamine in neurotransmission and brain diseases. Adv. Exp. Med. Biol. 2010, 709:95-107.
45. Pavon N., et al. ERK phosphorylation and FosB expression are associated with l-DOPA-induced dyskinesia in hemiparkinsonian mice. Biol. Psychiatry 2006, 59:64-74.
46. Pourcher E., Bonnet A.M., Kefalos J., Dubois B., Agid Y. Effects of etybenzatropine and diazepam on levodopa-induced diphasic dyskinesias in Parkinson's disease. Mov. Disord. Off. J. Mov. Disord. Soc. 1989, 4:195-201. 10.1002/mds.870040301.
47. Prast H., et al. Histaminergic neurons modulate acetylcholine release in the ventral striatum: role of H3 histamine receptors. Naunyn Schmiedebergs Arch Pharmacol. 1999, 360:558-564.
48. Rinne J.O., Anichtchik O.V., Eriksson K.S., Kaslin J., Tuomisto L., Kalimo H., Röyttä M., Panula P. Increased brain histamine levels in Parkinson's disease but not in multiple system atrophy. J. Neurochem. 2002, 81:954-960.
49. Santini E., et al. Inhibition of mTOR signaling in Parkinson's disease prevents l-DOPA-induced dyskinesia. Sci. Signal. 2009, 2:ra36.
50. Sciamanna G., Tassone A., Mandolesi G., Puglisi F., Ponterio G., Martella G., Madeo G., Bernardi G., Standaert D.G., Bonsi P., Pisani A. Cholinergic dysfunction alters synaptic integration between thalamostriatal and corticostriatal inputs in DYT1 dystonia. J. Neurosci. Off. J. Soc. Neurosci. 2012, 32:11991-12004. 10.1523/JNEUROSCI. 0041-12.2012.
51. Smythies J. Section I. The cholinergic system. Int. Rev. Neurobiol. 2005, 64:1-122. 10.1016/S0074-7742(05)64001-9.
52. Solis O., et al. Nitric oxide synthase inhibition decreases l-DOPA-induced dyskinesia and the expression of striatal molecular markers in Pitx3 aphakia mice. Neurobiol. Dis. 2015, 73:49-59.
53. Thomas A., Iacono D., Luciano A.L., Armellino K., Di Iorio A., Onofrj M. Duration of amantadine benefit on dyskinesia of severe Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 2004, 75:141-143.
54. Threlfell S., Lalic T., Platt N.J., Jennings K.A., Deisseroth K., Cragg S.J. Striatal dopamine release is triggered by synchronized activity in cholinergic interneurons. Neuron 2012, 75:58-64. 10.1016/j.neuron.2012.04.038.
55. Van den Munckhof P., Luk K.C., Ste-Marie L., Montgomery J., Blanchet P.J., Sadikot A.F., Drouin J. Pitx3 is required for motor activity and for survival of a subset of midbrain dopaminergic neurons. Dev. Camb. Engl. 2003, 130:2535-2542.
56. Varnum D.S., Stevens L.C. Aphakia, a new mutation in the mouse. J. Hered. 1968, 59:147-150.
57. Wilson C.J., Chang H.T., Kitai S.T. Firing patterns and synaptic potentials of identified giant aspiny interneurons in the rat neostriatum. J. Neurosci. Off. J. Soc. Neurosci. 1990, 10:508-519.
58. Wolf E., Seppi K., Katzenschlager R., Hochschorner G., Ransmayr G., Schwingenschuh P., Ott E., Kloiber I., Haubenberger D., Auff E., Poewe W. Long-term antidyskinetic efficacy of amantadine in Parkinson's disease. Mov. Disord. Off. J. Mov. Disord. Soc. 2010, 25:1357-1363. 10.1002/mds.23034.
59. Won L., Ding Y., Singh P., Kang U.J. Striatal cholinergic cell ablation attenuates l-DOPA induced dyskinesia in Parkinsonian mice. J. Neurosci. Off. J. Soc. Neurosci. 2014, 34:3090-3094. 10.1523/JNEUROSCI. 2888-13.2014.
60. Yanovsky Y., Li S., Klyuch B.P., Yao Q., Blandina P., Passani M.B., Lin J.-S., Haas H.L., Sergeeva O.A. l-Dopa activates histaminergic neurons. J. Physiol. 2011, 589:1349-1366. 10.1113/jphysiol.2010.203257.